<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:xhtml="http://www.w3.org/1999/xhtml">
<url><loc>https://www.vijoice-hcp.com/</loc><changefreq>daily</changefreq><priority>1.0</priority></url>
<url><loc>https://www.vijoice-hcp.com/sitemap</loc></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/patient-resources</loc><lastmod>2025-12-04T12:01Z</lastmod><changefreq>weekly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/access</loc><lastmod>2025-10-07T10:12Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/mechanism-of-action</loc><lastmod>2025-10-03T11:21Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/patient-profiles</loc><lastmod>2025-10-07T05:15Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/dosing-administration/tablets</loc><lastmod>2025-11-27T10:27Z</lastmod><changefreq>weekly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/dosing-administration/oral-granules</loc><lastmod>2025-10-03T11:23Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/pros-and-pik3ca-mutations/diagnosis</loc><lastmod>2025-10-03T11:21Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/efficacy/study-design</loc><lastmod>2025-10-03T11:28Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/efficacy/full-population</loc><lastmod>2025-10-03T11:28Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/efficacy/pediatric</loc><lastmod>2025-11-07T12:11Z</lastmod><changefreq>monthly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/efficacy/adult</loc><lastmod>2025-10-03T11:26Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/safety-profile/full-safety-profile</loc><lastmod>2025-10-03T11:26Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/safety-profile/growth-development</loc><lastmod>2025-10-07T14:50Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/pros-and-pik3ca-mutations/pros-disorders</loc><lastmod>2025-11-27T10:55Z</lastmod><changefreq>weekly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/coming-soon</loc><lastmod>2025-12-05T13:30Z</lastmod><changefreq>weekly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/dosing-administration/adults</loc><lastmod>2025-10-03T11:24Z</lastmod><changefreq>yearly</changefreq></url>
<url><loc>https://www.vijoice-hcp.com/products/vijoice/pik3ca-related-overgrowth-spectrum/dosing-administration/pediatrics</loc><lastmod>2025-10-03T11:25Z</lastmod><changefreq>yearly</changefreq></url>
</urlset>
